Vaccine Research in COVID-19: A Living Scoping Review Protocol

Vaccine Research in COVID-19: A Living Scoping Review Protocol | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Protocol Vaccine Research in COVID-19: A Living Scoping Review Protocol Jieyun Li, Lufang Feng, Haitong Zhao, Kehu Yang, Cuncun Lu This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-112777/v1 This work is licensed under a CC BY 4.0 License Status: Posted Version 1 posted You are reading this latest preprint version Abstract Background: Coronavirus disease 2019 (COVID-19) has become a global public problem and a pandemic event. Since the epidemic outbreak, deaths and cumulative confirmed positive cases have continued rising rapidly worldwide. Vaccines are regarded as one of the most effective means of preventing and controlling an epidemic. With the spread of COVID-19, a large number amount of literature on vaccines has been published recently. There is a pressing need to map the research activities of COVID-19 vaccines. Methods: Following Arksey and O’Malley’s framework and Joanna Briggs Institute (JBI) methodological guidance, a scoping review is proposed to summarize the extent/breadth, range, and nature of evidence in research related to COVID-19 vaccines. Based on the research questions we have developed by ours, a comprehensive search will be performed in Cochrane Library, Embase, PubMed, Web of Science, CNKI, CBM, VIP, and WanFang databases by two independent reviewers. According to our predefined inclusion criteria, pairs of reviewers will independently assess the eligibility of identified studies from the databases. Following literature selection, pairs of reviewers will extract relevant information related to our research questions. The methodological quality and reporting quality of key evidence types (i.e., randomized controlled trials, systematic reviews and meta-analyses) will be evaluated using commonly used tools, if possible. Qualitative synthesis and descriptive statistics will be used to summarize and present the results. In addition, new or updated meta-analysis will be conducted to pool the data available in included primary studies where possible. To track the trends in COVID-19 vaccines research, we plan to update our results every 2~3 months. Preparation of this scoping review protocol referred to PRISMA-P checklist, and the reporting of the following full-text will be using PRISMA-ScR guidelines. Discussion: We believe the results of this scoping review on COVID-19 vaccine will contribute to provide foundational knowledge, and have significant value for the research and practice of COVID-19 vaccines. The findings will also allow us to identify research gaps on this topic and help to guide the future research of COVID-19 vaccines well. Infectious Diseases Vaccine COVID-19 Research activity Living review Scoping review Background Since the beginning of 2020, the coronavirus disease 2019 (COVID-19) has swept the whole world, which has brought severe challenges to the politics, economy, and society of all countries [ 1 ]. Until November 14, 2020, there were more than 1.30 million deaths worldwide and a total of more than 53.61 million confirmed positive cases [ 2 ]. On the premise that the susceptible population has a large base and it is difficult to isolate the source of infection, especially the asymptomatic infection, the vaccine is widely regarded as one of the most effective means to prevent and control the epidemic. In terms of scale and speed, the current global research and development of the COVID-19 vaccines are unprecedented. Generally speaking, it usually takes 10 to 15 years for a kind of vaccine to be developed and put on the market [ 3 ], but this “convention” has been broken as the epidemic continues to spread around the world. After the genetic information of COVID-19 was made public [ 4 ], the global research and development of vaccines showed a high-speed, positive, and cautious trend [ 5 ]. According to the data released from the World Health Organization (WHO) on November 12, 2020, there are 212 known vaccines candidates in the world, of which 48 are in clinical evaluation and nine are in phase III clinical stage [ 6 ]. Vaccines under this report include the widely used traditional type of vaccines [ 7 ], namely the inactivated or attenuated vaccines [ 8 ], genetically engineered recombinant subunit adenovirus vector vaccines [ 9 – 11 ], recombinant viral vector vaccines [ 10 , 12 ], as well as new types of vaccines, ribonucleic acid (RNA) vaccines [ 13 ] and deoxyribonucleic acid (DNA) vaccines [ 14 ]. In addition to the safety and effectiveness of the vaccine has attracted worldwide attention, the public attitude towards the vaccine and the exploration and research on the accessibility of the vaccine have also been concerned. The public willingness to receive the COVID-19 vaccines in most of the 19 countries surveyed in one published study showed, is not sufficient to meet the requirements of community immunization [ 15 ]. At the same time, the study discovered that the accelerated pace of vaccines development may further increase public anxiety and endanger public acceptance [ 15 ]. One study suggested that vaccines in remote and poor areas are difficult to ensure cold chain transportation due to their remote geographical location, lack of cold storage conditions, high cold storage costs, and lack of economic capacity. These reasons largely limit the popularity of vaccines [ 16 ]. WHO launched “COVID-19 Vaccine implementation Plan” (COVAX) in September, 2020 ( https://www.who.int/initiatives/act-accelerator/covax ), the funds invested by countries joined in the COVAX have been pooled to cooperate in vaccines research production, and procurement agreements, to reduce vaccines’ prices, and promote fair access to vaccines for people in all countries/regions. With the spread of COVID-19, a large amount of literature on vaccines is being published recently. However, quantity is not the same as quality. On the contrary, too much information may confuse the decisions and choices of health decision-makers, clinicians, and researchers [ 17 ]. Meanwhile, overlapped, redundant and useless research may lead to avoidable waste of research [ 18 ]. As far as we know, the scientific research quality and integrity of vaccine-related research have not been directly evaluated, but the importance of doing so is self-evident [ 19 ]. The dissemination of misinformation may have a considerable impact on the acceptance of the COVID-19 vaccines. So far, it is not clear what evidence is available in the published vaccines’ literature and what decision-making references can be provided by this evidence. Additionally, it is not certain what are the knowledge gaps about the COVID-19 vaccines. Overall, since COVID-19 is new and the outcome of this pandemic is unknown [ 20 ], therefore, there is a pressing need to map the status quo and trends of COVID-19 vaccines research. A scoping review is different from the traditional systematic review [ 21 , 22 ]. It focuses on a broad range of research issues, can be used for mapping and disseminating the available evidence on a given area. It can not only to summarize the characteristics of existing publications, but clarify key concepts and their relationship, and identify the knowledge gaps in existing research. The methodological research of this method is making a continuous progress [ 23 , 24 ]. In particular, the reporting guidelines for this comprehensive type of evidence was published in 2018 [ 24 ]. Considering the objectives of our research and the advantages of this method, we will undertake a scoping review to synthesize the existing COVID-19 vaccines’ literatures. We will provide a comprehensive overview of the evidence and find gaps in knowledge, in order to inform the future vaccines research and clinical practice. Furthermore, the research will support governments and public health officials to spread reliable information of using COVID-19 vaccines, improving the popularization of vaccines knowledge so that the public can receive immunization. Methods/design Research design This scoping review will summarize COVID-19 vaccines research activities and describe the extent/breadth, range, and nature of evidence in research related to COVID-19 vaccines. The framework described by Arksey and O’Malley [25] and Joanna Briggs Institute (JBI) [23] methodological guidance has been followed to design this scoping review. The scoping review will involve five stages: 1) identifying the research question; 2) identifying relevant studies; 3) study selection; 4) charting the data; 5) collating, summarizing, and reporting results. The reporting of this protocol is based on the Preferred Reporting Items for Systematic Reviews and Meta Analyses protocols (PRISMA-P) checklist [26] (Additional file 1) and the full text will follow to Preferred Reporting Items for Systematic Reviews and Meta Analyses Extension for Scoping Reviews (PRISMA-ScR) guidelines [24]. This protocol has not been registered, because the International Prospective Register of Systematic Reviews (PROSPERO) website does not currently accept scoping reviews. As there are some uncertainties at protocol stage, if there are any deviations from the following full-text, we will report them in detail, as well as the reasons. Meanwhile, given the outbreak and vaccines research are still ongoing, our research team will update the results every 2-3 months. Stage 1: identifying the research question Following Arksey and O’Malley’s approach and JBI methodological guidance [25], this scoping review begins by formulating our research questions, which will guide the following processes that include whole of the subsequent literature search and study selection. We will focus on the following questions: The trends in publications of COVID-19 vaccines research (e.g., volume of publications, monthly distribution) and the bibliographic characteristics (e.g., journal, country, study type); The available evidence in the COVID-19 vaccines’ literatures and the pivotal points that they focusing on; The scientific quality of the critical evidence types (i.e., randomized controlled trials [RCTs], systematic reviews and meta-analyses) for COVID-19 vaccines, and if they adhering the best practices required by guidelines or tools (e.g., Consolidated Standards of Reporting Trials [CONSORT] [27], Preferred Reporting Items for Systematic Reviews and Meta Analyses[PRISMA] [24], A Measurement Tool to Assess Systematic Review 2 [AMSTAR 2]) [28]; The knowledge gaps in COVID-19 vaccines research, and critical questions that should be focused and addressed in the future. Stage 2: identifying relevant studies This stage will involve the creation of a comprehensive search strategy for identifying literature from the public databases for answering our research questions. Firstly, the potential main search terms have been determined by reading relevant literatures. Then the initial search strategy was established through discussion by the research team. Lastly, our final search strategy was confirmed after improvement and modification through repeating searches (Additional file 2). According to the final search strategy, we will search the eight widely-used databases including Cochrane Library, PubMed, EMBASE, Web of Science, CNKI, WanFang, CBM and VIP. The search will be run by two reviewers independently. The main keywords used in our search strategy include “COVID19”, “COVID-19”, “COVID2019”, “COVID-2019”, “2019 novel coronavirus infection”, “2019-nCoV”, “coronavirus disease 2019”, “coronavirus disease-19”, “Wuhan coronavirus”, “SARS-CoV-2”, “2019 novel coronavirus”, “Wuhan-Cov”, “Wuhan seafood market pneumonia virus”, “Wuhan virus”, “novel coronavirus pneumonia”, “Severe acute respiratory syndrome-related coronavirus”, “Novel CoV”, “severe acute respiratory syndrome coronavirus 2”, “Vaccination Coverage”, “Vaccin*”, “Vacuna”, “Inoculation”, “Immunization Programs”, etc. Additionally, we will manually check the reference list of included literatures. Although many published COVID-19 reviews searched preprint servers, e.g., bioRxiv ( https://www.biorxiv.org/ ), medRxiv ( https://www.medrxiv.org/ ), we will not to do so as we only include published papers that have been peer-reviewed (even if the article is retracted after publication), whereas preprint servers manuscripts are not peer-reviewed. Stage 3: study selection Following the recommendations made by Levac et al [29], pairs of reviewers will independently screen the titles, abstracts and full-texts to identify potentially relevant studies. We will use literature management software to complete the literature selection process. After deduplication, an online application Rayyan [30] will be used for screening of abstracts and titles using a process of semi-automation, then Endnote X9 (Thomson Corporation) will be used to assess the eligibility of full-texts. In order to improve the accuracy of the included literature and the consistency of subsequent screening across reviewers, prior to formal screening, the pre-test will be conducted to familiarize the research content and strengthen the understanding for this topic of team members by screening 200 sample records randomly selected. After completing the pre-test, the other records will be screened according to the aforementioned process. Any disagreements during the selection process will be resolved by discussion. The inclusion and exclusion criteria in our scoping review are as follows: 1) all qualitive, quantitative or mix-method research focusing on COVID-19 vaccines will be included; 2) no limitation on study types, they could be but not limited to guidance documents, basic experiments, clinical studies (e.g., RCTs, cohort studies, cross-sectional studies and case reports), any reviews (e.g., expert reviews, systematic reviews and meta-analyses), conference articles, protocols, and retracted articles (for exploring the issues regarding the integrity of science in the period of COVID-19); 3) we will not limit the research topic for mapping the full landscape for COVID-19 vaccines research, these topics can involve efficacy and safety, cost, public attitudes, views and perceptions, but not limited to that; 4) we will include Chinese and English documents only; 5) we will exclude any news and full-text documents which are not available. Stage 4: charting the data A self-developed Excel sheet will be used to extract data, which the relevant information we needed to complete the review. The mainly extracted information including: title, the first author, online or publication date, journal, setting/study location (where the study was conducted), origin/country of corresponding author (where the paper was published), study aim/purpose, study population and sample size, study topic, methodology/method (e.g., framework ), type of vaccines and comparator (if any) and duration of intervention, study type, outcome measures, and important findings or conclusions that relate to our research questions in this scoping review. Before the formal extraction beginning, pairs of reviewers will pilot the data extraction form by using a sample comprising 10% of the included documents. After the completion of pre-data extraction, the results abstracted by them will be cross-checked and consensus will be sought through discussion, so as to further improve the form until the results are no obvious conflict across data extractors, and then the formal extraction will be completed by pairs of reviewers. Any disagreement will be resolved by discussion within all team members. In addition, although quality assessment is not required by the scoping review methodology [25], considering the reliability and application of the study conclusion may be affected by the methodology design and reporting of the study; RCTs, systematic reviews and meta-analyses as important types of evidence will be selected to assess their scientific quality, if possible. Thus, four validated tools, risk of bias 2.0 (RoB 2.0) [31] and CONSORT 2010, AMSTAR 2 and PRISMA will be used to assess the methodological quality and reporting quality of RCTs, and systematic reviews and meta-analyses, respectively. Stage 5: collating, summarizing, and reporting results We will use the PRISMA flow diagram to report the process for literatures screening, the reasons for excluded and final number of included publications in our scoping review. Qualitative synthesis (thematic analysis method [32]) and descriptive statistics will be used to summarize and present the results. Descriptive statistics (e.g., frequency and percentage) will be used to report the general characteristics (e.g., journal, country, and study type, volume of publications) of included literatures. According to the research contents reported in included documents and study topics they focused on, the COVID-19 vaccines research will be gathered as different themes and their sub-themes (e.g., efficacy and safety, cost, public attitudes, views, and perceptions). In addition, new or updated meta-analysis will be conducted to pool the data available in included primary studies, if relevant. Discussion Our scoping review is designed for mapping COVID-19 vaccines research activities and to describe the extent/breadth, range, and nature of evidence in research related to COVID-19 vaccines. We believe this scoping review will not only provide meta-data regarding analysis and summary of existing research on COVID-19 vaccines research, but provide profound knowledge and robust evidence for the global research community. To date, many studies had reported some positive conclusions from the efficacy and safety of COVID-19 vaccines [ 10 , 11 , 13 ]. For example, one study had shown that the upper and lower respiratory tracts in mice and ferrets can be completely protected against SARS-COV-2 infection by single inoculations of the adenovirus type 5based COVID-19 vaccine (Ad5-nCoV) in mucous membranes and intramuscularly [ 10 ]. It also gives us a hint that the different routes of vaccination should be considered in human clinical trials for the development of the SARS-CoV-2 vaccines. In addition to the research on the vaccine itself, the universality and public acceptance of the vaccine also need to be considered. At the same time, to win the battle against the COVID-19 pandemic as soon as possible, some more efforts are needed that involve in increasing cooperation among countries and regions, improving the quality of scientific research, and establishing a comprehensive surveillance system. Scoping review is a popular approach to address the uncertainty of evidence in a wide research topic [ 22 , 23 ]. Considering this method allows us to conduct an in-depth exploration of the existing evidence, therefore, we choose this approach to mapping the research activity related to COVID-19 vaccines. This present protocol reports a comprehensive, rigorous, and transparent methodology regarding our scoping review, we will follow this protocol to complete our research. Hopefully, the evidence identified from the literature in our scoping review can provide government and public health officials with reference to the implementation of COVID-19 vaccines. Meanwhile, knowledge gaps identified in the current body of literatures can guide future COVID-19 vaccines research. To our knowledge, this will be the first scoping review of COVID-19 vaccines, and the results of this review will have a significant value for all stakeholders. Nevertheless, we only searched the commonly used Chinese and English databases, and the literatures in Chinese and English will be only included. Given that COVID-19 vaccine is a global problem, some important research reports published with other languages may be missed. This would be a notable limitation of our scoping review. Ethics and dissemination Since the data will be collected from publicly available materials, this study does not require an ethical approval. The results of our scoping review will be disseminated through a peer-reviewed publication, targeting an audience involved in all stakeholders, e.g., medical researchers and clinicians and public health officials. Abbreviations Ad5-nCoV : Adenovirus type 5based COVID-19 vaccine; AMSTAR 2 : A Measurement Tool to Assess Systematic Review 2; CONSORT : Consolidated Standards of Reporting Trials; COVAX : COVID-19 Vaccine implementation Plan; COVID-19 : Coronavirus disease 2019; DNA : Deoxyribonucleic acid; JBI : Joanna Briggs Institute; PRISMA : Preferred Reporting Items for Systematic Reviews and Meta Analyses; PRISMA-P : Preferred Reporting Items for Systematic Reviews and Meta Analyses protocols; PRISMA-ScR : Preferred Reporting Items for Systematic Reviews and Meta Analyses Extension for Scoping Reviews; PROSPERO : International Prospective Register of Systematic Reviews; RCTs : Randomized controlled trials; RNA : Ribonucleic acid; RoB 2.0 : Risk of bias 2.0; SARS-CoV-2 : Severe acute respiratory syndrome-related coronavirus 2; WHO : World Health Organization. Declarations Ethics approval and consent to participate Research ethics board approval and consent were waived, because the conduct of this research will be based on published literature. Consent for publication Not applicable. Availability of data and materials All data generated or analyzed during this research will be included in the following full-text of the scoping review and/or its supplementary files. Competing interests The authors declare that they have no competing interests. Funding None. Authors’ contributions Cuncun Lu developed the research questions, the rest of other authors modified and improved them. Jieyun Li, Lufang Feng, Haitong Zhao and Kehu Yang established the search strategy. Jieyun Li, Lufang Feng and Cuncun Lu drafted the protocol. Jieyun Li, Lufang Feng, Haitong Zhao, Kehu Yang and Cuncun Lu reviewed and approved the final manuscript. Acknowledgements The authors thank Howard White (Chief Executive Officer of Campbell Collaboration, Methodological expert) for his methodological guidance and proofreading of the manuscript. References Kaur SP, and Gupta V. COVID-19 Vaccine: A comprehensive status report. Virus Res. 2020; 288:198114. WHO, WHO Coronavirus Disease (COVID-19) Dashboard https://covid19.who.int/ . [Accessed on November 14, 2020] Cunningham AL, Garçon N, Leo O, Friedland LR, Strugnell R, Laupèze B, et al. Vaccine development: From concept to early clinical testing. Vaccine. 2016;34(52):6655-6664. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270-273. Graham BS. Rapid COVID-19 vaccine development. Science. 2020;368(6494):945-946. WHO, DRAFT landscape of COVID-19 candidate vaccines https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines /. [Accessed on November 14, 2020] Doshi P, Will covid-19 vaccines save lives? Current trials aren't designed to tell us. BMJ. 2020;371:m4037. Seo SH and Y. Jang. Cold-adapted live attenuated sars-cov-2 vaccine completely protects human ace2 transgenic mice from sars-cov-2 infection. Vaccines. 2020;8(4):1-17. Zost SJ, Gilchuk P, Case JB, Binshtein E, Chen RE, Nkolola JP, et al. Potently neutralizing and protective human antibodies against SARS-CoV-2. Nature. 2020;584(7821):443-449. Wu S, Zhong G, Zhang J, Shuai L, Zhang Z, Wen Z, et al. A single dose of an adenovirus-vectored vaccine provides protection against SARS-CoV-2 challenge. Nat Commun. 2020;11(1):4081. Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020;396(10249):467-478. Li L, Guo P, Zhang X, Yu Z, Zhang W and Sun H. SARS-CoV-2 vaccine candidates in rapid development. Human Vaccines and Immunotherapeutics. 2020. Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, et al. An mRNA Vaccine against SARS-CoV-2-Preliminary Report. N Engl J Med. 2020;383(20):1920-1931. Theobald N. Emerging vaccine delivery systems for COVID-19: Functionalised silica nanoparticles offer a potentially safe and effective alternative delivery system for DNA/RNA vaccines and may be useful in the hunt for a COVID-19 vaccine. Drug Discov Today. 2020;25(9):1556-1558. Lazarus JV, Ratzan SC, Palayew A, Gostin LO, Larson HJ, Rabin K, et al. A global survey of potential acceptance of a COVID-19 vaccine. Nat Med. 2020;1-4. Chen SY, Zhang C, Huang XF, Wang X, Zhao QJ. Enhanced vaccine accessibility through innovative regulatory sciences. Chin J New Drugs. 2017;26(20):2369-2375. [In Chinese] Bastian H, Glasziou P and Chalmers I. Seventy-five trials and eleven systematic reviews a day: how will we ever keep up? PLoS Med. 2010;7(9):e1000326. Chalmers I, and Glasziou P. Avoidable waste in the production and reporting of research evidence. Lancet. 2009;374(9683):86-89. Bagdasarian N, Cross GB and Fisher D. Rapid publications risk the integrity of science in the era of COVID-19. BMC Med. 2020;8(1):192. de Wit E, van Doremalen N, Falzarano D and Munster VJ. SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol. 2016;14(8):523-534. Munn Z, Peters MDJ, Stern C, Tufanaru C, McArthur A and Aromataris E. Systematic review or scoping review? Guidance for authors when choosing between a systematic or scoping review approach. BMC Med Res Methodol. 2018;18(1):143. Tricco AC, Lillie E, Zarin W, O'Brien K, Colquhoun H, Kastner M, et al. A scoping review on the conduct and reporting of scoping reviews. BMC Med Res Methodol.2016;6:15. Peters MDJ, Marnie C, Tricco AC, Pollock D, Munn Z, Alexander L, et al. Updated methodological guidance for the conduct of scoping reviews. JBI Evid Synth. 2020;18(10):2119-2126. Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. Ann Intern Med. 2018;169(7):467-473. Arksey H and O'Malley L. Scoping studies: towards a methodological framework. International Journal of Social Research Methodology. 2005;8(1):19-32. Moher D, Liberati A, Tetzlaff J and Altman DG, Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7): e1000097. Schulz KF, Altman DG and Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ. 2010;340:c332. Shea BJ, Reeves BC, Wells G, Thuku M, Hamel C, Moran J, et al., AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ. 2017;358: j4008. Levac D, Colquhoun H and O'Brien KK, Scoping studies: advancing the methodology. Implementation Science. 2010;5(1):69. Ouzzani M, Hammady H, Fedorowicz Z and Elmagarmid A, Rayyan-a web and mobile app for systematic reviews. Syst Rev. 2016;5(1):210. Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. Vaismoradi M, Turunen H and Bondas T. Content analysis and thematic analysis: Implications for conducting a qualitative descriptive study. Nurs Health Sci. 2013;15(3):398-405. Supplementary Files Additionalfile1.docx Additionalfile2.docx Cite Share Download PDF Status: Posted Version 1 posted You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-112777","acceptedTermsAndConditions":true,"allowDirectSubmit":true,"archivedVersions":[],"articleType":"Protocol","associatedPublications":[],"authors":[{"id":5100456,"identity":"2f343d65-3381-48d6-ad1c-a85ed19c99f9","order_by":0,"name":"Jieyun Li","email":"","orcid":"","institution":"Lanzhou University","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Jieyun","middleName":"","lastName":"Li","suffix":""},{"id":5100457,"identity":"0418ddc7-687d-42f0-9fed-ec76de40d30b","order_by":1,"name":"Lufang Feng","email":"","orcid":"","institution":"Lanzhou University","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Lufang","middleName":"","lastName":"Feng","suffix":""},{"id":5100458,"identity":"32127485-977b-4aad-800f-09eb0f3f10bc","order_by":2,"name":"Haitong Zhao","email":"","orcid":"","institution":"Lanzhou University","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Haitong","middleName":"","lastName":"Zhao","suffix":""},{"id":5100459,"identity":"d16d10c7-8a4b-4119-90e7-72674d819652","order_by":3,"name":"Kehu Yang","email":"","orcid":"","institution":"Lanzhou University","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Kehu","middleName":"","lastName":"Yang","suffix":""},{"id":5100460,"identity":"54bcf83c-d816-4b41-a00e-6a128e4242c5","order_by":4,"name":"Cuncun Lu","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAAA1ElEQVRIiWNgGAWjYPACCwZ+Zsb2Hx8MbOyI1SLBINne3CA5oyAtmXgtBmeON0jzfDjE2EBILf+M3IOfeXdIJDbcSGwwtjE4wMzAfvjoBrzG38hLluY9I5HYOCOxITnH4A4fA09a2g18WgwkcsyYedskEpuBFh3OMXjGzCDBY0acFiBqbLYwOMzYQLSWHp6DzcwMxGiROPPGWHJum4TxDPbGNsYeg7RkNkJ+4W/PMfzwts1Gdv9h9mcMP/7Y2PGzHz6GVwsmYCNN+SgYBaNgFIwCbAAArq5GXBKUToYAAAAASUVORK5CYII=","orcid":"https://orcid.org/0000-0001-9541-9733","institution":"Lanzhou University","correspondingAuthor":true,"submittingAuthor":false,"prefix":"","firstName":"Cuncun","middleName":"","lastName":"Lu","suffix":""}],"badges":[],"createdAt":"2020-11-20 16:24:10","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-112777/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-112777/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":13617253,"identity":"55a81448-7956-4b83-9ad9-1de3c1a44c0f","added_by":"auto","created_at":"2021-09-17 06:53:04","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":314552,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-112777/v1/3cf60f40-c8e4-4880-a900-e39cfcb8a986.pdf"},{"id":3777929,"identity":"67a049a7-82ee-4a98-a8fb-2a9f76280100","added_by":"auto","created_at":"2020-11-23 22:30:16","extension":"docx","order_by":1,"title":"","display":"","copyAsset":false,"role":"supplement","size":18666,"visible":true,"origin":"","legend":"","description":"","filename":"Additionalfile1.docx","url":"https://assets-eu.researchsquare.com/files/rs-112777/v1/ea9ed0a31312aebd956772b5.docx"},{"id":3777930,"identity":"ed6f8224-6676-4ac2-b457-8fdec567cc28","added_by":"auto","created_at":"2020-11-23 22:30:16","extension":"docx","order_by":2,"title":"","display":"","copyAsset":false,"role":"supplement","size":19439,"visible":true,"origin":"","legend":"","description":"","filename":"Additionalfile2.docx","url":"https://assets-eu.researchsquare.com/files/rs-112777/v1/43069bd348e4eecefb78c63e.docx"}],"financialInterests":"","formattedTitle":"Vaccine Research in COVID-19: A Living Scoping Review Protocol","fulltext":[{"header":"Background","content":" \u003cp\u003eSince the beginning of 2020, the coronavirus disease 2019 (COVID-19) has swept the whole world, which has brought severe challenges to the politics, economy, and society of all countries [\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e]. Until November 14, 2020, there were more than 1.30\u0026nbsp;million deaths worldwide and a total of more than 53.61\u0026nbsp;million confirmed positive cases [\u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e]. On the premise that the susceptible population has a large base and it is difficult to isolate the source of infection, especially the asymptomatic infection, the vaccine is widely regarded as one of the most effective means to prevent and control the epidemic. In terms of scale and speed, the current global research and development of the COVID-19 vaccines are unprecedented.\u003c/p\u003e \u003cp\u003eGenerally speaking, it usually takes 10 to 15\u0026nbsp;years for a kind of vaccine to be developed and put on the market [\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e], but this \u0026ldquo;convention\u0026rdquo; has been broken as the epidemic continues to spread around the world. After the genetic information of COVID-19 was made public [\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e], the global research and development of vaccines showed a high-speed, positive, and cautious trend [\u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e]. According to the data released from the World Health Organization (WHO) on November 12, 2020, there are 212 known vaccines candidates in the world, of which 48 are in clinical evaluation and nine are in phase III clinical stage [\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e]. Vaccines under this report include the widely used traditional type of vaccines [\u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e], namely the inactivated or attenuated vaccines [\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e], genetically engineered recombinant subunit adenovirus vector vaccines [\u003cspan additionalcitationids=\"CR10\" citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e], recombinant viral vector vaccines [\u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e, \u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e], as well as new types of vaccines, ribonucleic acid (RNA) vaccines [\u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e] and deoxyribonucleic acid (DNA) vaccines [\u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eIn addition to the safety and effectiveness of the vaccine has attracted worldwide attention, the public attitude towards the vaccine and the exploration and research on the accessibility of the vaccine have also been concerned. The public willingness to receive the COVID-19 vaccines in most of the 19 countries surveyed in one published study showed, is not sufficient to meet the requirements of community immunization [\u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e]. At the same time, the study discovered that the accelerated pace of vaccines development may further increase public anxiety and endanger public acceptance [\u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e]. One study suggested that vaccines in remote and poor areas are difficult to ensure cold chain transportation due to their remote geographical location, lack of cold storage conditions, high cold storage costs, and lack of economic capacity. These reasons largely limit the popularity of vaccines [\u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e]. WHO launched \u0026ldquo;COVID-19 Vaccine implementation Plan\u0026rdquo; (COVAX) in September, 2020 (\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://www.who.int/initiatives/act-accelerator/covax\u003c/span\u003e\u003c/span\u003e), the funds invested by countries joined in the COVAX have been pooled to cooperate in vaccines research production, and procurement agreements, to reduce vaccines\u0026rsquo; prices, and promote fair access to vaccines for people in all countries/regions.\u003c/p\u003e \u003cp\u003eWith the spread of COVID-19, a large amount of literature on vaccines is being published recently. However, quantity is not the same as quality. On the contrary, too much information may confuse the decisions and choices of health decision-makers, clinicians, and researchers [\u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e]. Meanwhile, overlapped, redundant and useless research may lead to avoidable waste of research [\u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e18\u003c/span\u003e]. As far as we know, the scientific research quality and integrity of vaccine-related research have not been directly evaluated, but the importance of doing so is self-evident [\u003cspan citationid=\"CR19\" class=\"CitationRef\"\u003e19\u003c/span\u003e]. The dissemination of misinformation may have a considerable impact on the acceptance of the COVID-19 vaccines. So far, it is not clear what evidence is available in the published vaccines\u0026rsquo; literature and what decision-making references can be provided by this evidence. Additionally, it is not certain what are the knowledge gaps about the COVID-19 vaccines. Overall, since COVID-19 is new and the outcome of this pandemic is unknown [\u003cspan citationid=\"CR20\" class=\"CitationRef\"\u003e20\u003c/span\u003e], therefore, there is a pressing need to map the status quo and trends of COVID-19 vaccines research.\u003c/p\u003e \u003cp\u003eA scoping review is different from the traditional systematic review [\u003cspan citationid=\"CR21\" class=\"CitationRef\"\u003e21\u003c/span\u003e, \u003cspan citationid=\"CR22\" class=\"CitationRef\"\u003e22\u003c/span\u003e]. It focuses on a broad range of research issues, can be used for mapping and disseminating the available evidence on a given area. It can not only to summarize the characteristics of existing publications, but clarify key concepts and their relationship, and identify the knowledge gaps in existing research. The methodological research of this method is making a continuous progress [\u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e, \u003cspan citationid=\"CR24\" class=\"CitationRef\"\u003e24\u003c/span\u003e]. In particular, the reporting guidelines for this comprehensive type of evidence was published in 2018 [\u003cspan citationid=\"CR24\" class=\"CitationRef\"\u003e24\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eConsidering the objectives of our research and the advantages of this method, we will undertake a scoping review to synthesize the existing COVID-19 vaccines\u0026rsquo; literatures. We will provide a comprehensive overview of the evidence and find gaps in knowledge, in order to inform the future vaccines research and clinical practice. Furthermore, the research will support governments and public health officials to spread reliable information of using COVID-19 vaccines, improving the popularization of vaccines knowledge so that the public can receive immunization.\u003c/p\u003e "},{"header":"Methods/design","content":"\u003ch2\u003eResearch design\u003c/h2\u003e\n\u003cp\u003eThis scoping review will summarize COVID-19 vaccines research activities and describe the extent/breadth, range, and nature of evidence in research related to COVID-19 vaccines. The framework described by Arksey and O\u0026rsquo;Malley [25] and Joanna Briggs Institute (JBI) [23] methodological guidance has been followed to design this scoping review. The scoping review will involve five stages: 1) identifying the research question; 2) identifying relevant studies; 3) study selection; 4) charting the data; 5) collating, summarizing, and reporting results. The reporting of this protocol is based on the Preferred Reporting Items for Systematic Reviews and Meta Analyses protocols (PRISMA-P) checklist [26] (Additional file 1) and the full text will follow to Preferred Reporting Items for Systematic Reviews and Meta Analyses Extension for Scoping Reviews (PRISMA-ScR) guidelines [24]. This protocol has not been registered, because the International Prospective Register of Systematic Reviews (PROSPERO) website does not currently accept scoping reviews. As there are some uncertainties at protocol stage, if there are any deviations from the following full-text, we will report them in detail, as well as the reasons. Meanwhile, given the outbreak and vaccines research are still ongoing, our research team will update the results every 2-3 months.\u003c/p\u003e\n\u003ch2\u003eStage 1: identifying the research question\u003c/h2\u003e\n\u003cp\u003eFollowing Arksey and O\u0026rsquo;Malley\u0026rsquo;s approach and JBI methodological guidance [25], this scoping review begins by formulating our research questions, which will guide the following processes that include whole of the subsequent literature search and study selection. We will focus on the following questions:\u003c/p\u003e\n\u003col\u003e\n\u003cli\u003e\n\u003cp\u003eThe trends in publications of COVID-19 vaccines research (e.g., volume of publications, monthly distribution) and the bibliographic characteristics (e.g., journal, country, study type);\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eThe available evidence in the COVID-19 vaccines\u0026rsquo; literatures and the pivotal points that they focusing on;\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eThe scientific quality of the critical evidence types (i.e., randomized controlled trials [RCTs], systematic reviews and meta-analyses) for COVID-19 vaccines, and if they adhering the best practices required by guidelines or tools (e.g., Consolidated Standards of Reporting Trials [CONSORT] [27], Preferred Reporting Items for Systematic Reviews and Meta Analyses[PRISMA] [24], A Measurement Tool to Assess Systematic Review 2 [AMSTAR 2]) [28];\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eThe knowledge gaps in COVID-19 vaccines research, and critical questions that should be focused and addressed in the future.\u003c/p\u003e\n\u003c/li\u003e\n\u003c/ol\u003e\n\u003ch2\u003eStage 2: identifying relevant studies\u003c/h2\u003e\n\u003cp\u003eThis stage will involve the creation of a comprehensive search strategy for identifying literature from the public databases for answering our research questions. Firstly, the potential main search terms have been determined by reading relevant literatures. Then the initial search strategy was established through discussion by the research team. Lastly, our final search strategy was confirmed after improvement and modification through repeating searches (Additional file 2). According to the final search strategy, we will search the eight widely-used databases including Cochrane Library, PubMed, EMBASE, Web of Science, CNKI, WanFang, CBM and VIP. The search will be run by two reviewers independently. The main keywords used in our search strategy include \u0026ldquo;COVID19\u0026rdquo;, \u0026ldquo;COVID-19\u0026rdquo;, \u0026ldquo;COVID2019\u0026rdquo;, \u0026ldquo;COVID-2019\u0026rdquo;, \u0026ldquo;2019 novel coronavirus infection\u0026rdquo;, \u0026ldquo;2019-nCoV\u0026rdquo;, \u0026ldquo;coronavirus disease 2019\u0026rdquo;, \u0026ldquo;coronavirus disease-19\u0026rdquo;, \u0026ldquo;Wuhan coronavirus\u0026rdquo;, \u0026ldquo;SARS-CoV-2\u0026rdquo;, \u0026ldquo;2019 novel coronavirus\u0026rdquo;, \u0026ldquo;Wuhan-Cov\u0026rdquo;, \u0026ldquo;Wuhan seafood market pneumonia virus\u0026rdquo;, \u0026ldquo;Wuhan virus\u0026rdquo;, \u0026ldquo;novel coronavirus pneumonia\u0026rdquo;, \u0026ldquo;Severe acute respiratory syndrome-related coronavirus\u0026rdquo;, \u0026ldquo;Novel CoV\u0026rdquo;, \u0026ldquo;severe acute respiratory syndrome coronavirus 2\u0026rdquo;, \u0026ldquo;Vaccination Coverage\u0026rdquo;, \u0026ldquo;Vaccin*\u0026rdquo;, \u0026ldquo;Vacuna\u0026rdquo;, \u0026ldquo;Inoculation\u0026rdquo;, \u0026ldquo;Immunization Programs\u0026rdquo;, etc. Additionally, we will manually check the reference list of included literatures. Although many published COVID-19 reviews searched preprint servers, e.g., bioRxiv (\u003ca href=\"https://www.biorxiv.org/\"\u003ehttps://www.biorxiv.org/\u003c/a\u003e), medRxiv (\u003ca href=\"https://www.medrxiv.org/\"\u003ehttps://www.medrxiv.org/\u003c/a\u003e), we will not to do so as we only include published papers that have been peer-reviewed (even if the article is retracted after publication), whereas preprint servers manuscripts are not peer-reviewed.\u003c/p\u003e\n\u003ch2\u003eStage 3: study selection\u003c/h2\u003e\n\u003cp\u003eFollowing the recommendations made by Levac et al [29], pairs of reviewers will independently screen the titles, abstracts and full-texts to identify potentially relevant studies. We will use literature management software to complete the literature selection process. After deduplication, an online application Rayyan [30] will be used for screening of abstracts and titles using a process of semi-automation, then Endnote X9 (Thomson Corporation) will be used to assess the eligibility of full-texts. In order to improve the accuracy of the included literature and the consistency of subsequent screening across reviewers, prior to formal screening, the pre-test will be conducted to familiarize the research content and strengthen the understanding for this topic of team members by screening 200 sample records randomly selected. After completing the pre-test, the other records will be screened according to the aforementioned process. Any disagreements during the selection process will be resolved by discussion.\u003c/p\u003e\n\u003cp\u003eThe inclusion and exclusion criteria in our scoping review are as follows: 1) all qualitive, quantitative or mix-method research focusing on COVID-19 vaccines will be included; 2) no limitation on study types, they could be but not limited to guidance documents, basic experiments, clinical studies (e.g., RCTs, cohort studies, cross-sectional studies and case reports), any reviews (e.g., expert reviews, systematic reviews and meta-analyses), conference articles, protocols, and retracted articles (for exploring the issues regarding the integrity of science in the period of COVID-19); 3) we will not limit the research topic for mapping the full landscape for COVID-19 vaccines research, these topics can involve efficacy and safety, cost, public attitudes, views and perceptions, but not limited to that; 4) we will include Chinese and English documents only; 5) we will exclude any news and full-text documents which are not available.\u003c/p\u003e\n\u003ch2\u003eStage 4: charting the data\u003c/h2\u003e\n\u003cp\u003eA self-developed Excel sheet will be used to extract data, which the relevant information we needed to complete the review. The mainly extracted information including: title, the first author, online or publication date, journal, setting/study location (where the study was conducted), origin/country of corresponding author (where the paper was published), study aim/purpose, study population and sample size, study topic, methodology/method (e.g., framework ), type of vaccines and comparator (if any) and duration of intervention, study type, outcome measures, and important findings or conclusions that relate to our research questions in this scoping review.\u003c/p\u003e\n\u003cp\u003eBefore the formal extraction beginning, pairs of reviewers will pilot the data extraction form by using a sample comprising 10% of the included documents. After the completion of pre-data extraction, the results abstracted by them will be cross-checked and consensus will be sought through discussion, so as to further improve the form until the results are no obvious conflict across data extractors, and then the formal extraction will be completed by pairs of reviewers. Any disagreement will be resolved by discussion within all team members.\u003c/p\u003e\n\u003cp\u003eIn addition, although quality assessment is not required by the scoping review methodology [25], considering the reliability and application of the study conclusion may be affected by the methodology design and reporting of the study; RCTs, systematic reviews and meta-analyses as important types of evidence will be selected to assess their scientific quality, if possible. Thus, four validated tools, risk of bias 2.0 (RoB 2.0) [31] and CONSORT 2010, AMSTAR 2 and PRISMA will be used to assess the methodological quality and reporting quality of RCTs, and systematic reviews and meta-analyses, respectively.\u003c/p\u003e\n\u003ch2\u003eStage 5: collating, summarizing, and reporting results\u003c/h2\u003e\n\u003cp\u003eWe will use the PRISMA flow diagram to report the process for literatures screening, the reasons for excluded and final number of included publications in our scoping review. Qualitative synthesis (thematic analysis method [32]) and descriptive statistics will be used to summarize and present the results. Descriptive statistics (e.g., frequency and percentage) will be used to report the general characteristics (e.g., journal, country, and study type, volume of publications) of included literatures. According to the research contents reported in included documents and study topics they focused on, the COVID-19 vaccines research will be gathered as different themes and their sub-themes (e.g., efficacy and safety, cost, public attitudes, views, and perceptions). In addition, new or updated meta-analysis will be conducted to pool the data available in included primary studies, if relevant.\u003c/p\u003e"},{"header":"Discussion","content":"\u003cp\u003eOur scoping review is designed for mapping COVID-19 vaccines research activities and to describe the extent/breadth, range, and nature of evidence in research related to COVID-19 vaccines. We believe this scoping review will not only provide meta-data regarding analysis and summary of existing research on COVID-19 vaccines research, but provide profound knowledge and robust evidence for the global research community.\u003c/p\u003e\n\u003cp\u003eTo date, many studies had reported some positive conclusions from the efficacy and safety of COVID-19 vaccines [\u003cspan class=\"CitationRef\"\u003e10\u003c/span\u003e, \u003cspan class=\"CitationRef\"\u003e11\u003c/span\u003e, \u003cspan class=\"CitationRef\"\u003e13\u003c/span\u003e]. For example, one study had shown that the upper and lower respiratory tracts in mice and ferrets can be completely protected against SARS-COV-2 infection by single inoculations of the adenovirus type 5based COVID-19 vaccine (Ad5-nCoV) in mucous membranes and intramuscularly [\u003cspan class=\"CitationRef\"\u003e10\u003c/span\u003e]. It also gives us a hint that the different routes of vaccination should be considered in human clinical trials for the development of the SARS-CoV-2 vaccines. In addition to the research on the vaccine itself, the universality and public acceptance of the vaccine also need to be considered. At the same time, to win the battle against the COVID-19 pandemic as soon as possible, some more efforts are needed that involve in increasing cooperation among countries and regions, improving the quality of scientific research, and establishing a comprehensive surveillance system.\u003c/p\u003e\n\u003cp\u003eScoping review is a popular approach to address the uncertainty of evidence in a wide research topic [\u003cspan class=\"CitationRef\"\u003e22\u003c/span\u003e, \u003cspan class=\"CitationRef\"\u003e23\u003c/span\u003e]. Considering this method allows us to conduct an in-depth exploration of the existing evidence, therefore, we choose this approach to mapping the research activity related to COVID-19 vaccines. This present protocol reports a comprehensive, rigorous, and transparent methodology regarding our scoping review, we will follow this protocol to complete our research. Hopefully, the evidence identified from the literature in our scoping review can provide government and public health officials with reference to the implementation of COVID-19 vaccines. Meanwhile, knowledge gaps identified in the current body of literatures can guide future COVID-19 vaccines research. To our knowledge, this will be the first scoping review of COVID-19 vaccines, and the results of this review will have a significant value for all stakeholders. Nevertheless, we only searched the commonly used Chinese and English databases, and the literatures in Chinese and English will be only included. Given that COVID-19 vaccine is a global problem, some important research reports published with other languages may be missed. This would be a notable limitation of our scoping review.\u003c/p\u003e\n\u003ch2\u003eEthics and dissemination\u003c/h2\u003e\n\u003cp\u003eSince the data will be collected from publicly available materials, this study does not require an ethical approval. The results of our scoping review will be disseminated through a peer-reviewed publication, targeting an audience involved in all stakeholders, e.g., medical researchers and clinicians and public health officials.\u003c/p\u003e"},{"header":"Abbreviations","content":"\u003cp\u003e\u003cstrong\u003eAd5-nCoV\u003c/strong\u003e: Adenovirus type 5based COVID-19 vaccine; \u003cstrong\u003eAMSTAR 2\u003c/strong\u003e: A Measurement Tool to Assess Systematic Review 2; \u003cstrong\u003eCONSORT\u003c/strong\u003e: Consolidated Standards of Reporting Trials; \u003cstrong\u003eCOVAX\u003c/strong\u003e: COVID-19 Vaccine implementation Plan; \u003cstrong\u003eCOVID-19\u003c/strong\u003e: Coronavirus disease 2019; \u003cstrong\u003eDNA\u003c/strong\u003e: Deoxyribonucleic acid; \u003cstrong\u003eJBI\u003c/strong\u003e: Joanna Briggs Institute; \u003cstrong\u003ePRISMA\u003c/strong\u003e: Preferred Reporting Items for Systematic Reviews and Meta Analyses; \u003cstrong\u003ePRISMA-P\u003c/strong\u003e: Preferred Reporting Items for Systematic Reviews and Meta Analyses protocols; \u003cstrong\u003ePRISMA-ScR\u003c/strong\u003e: Preferred Reporting Items for Systematic Reviews and Meta Analyses Extension for Scoping Reviews; \u003cstrong\u003ePROSPERO\u003c/strong\u003e: International Prospective Register of Systematic Reviews; \u003cstrong\u003eRCTs\u003c/strong\u003e: Randomized controlled trials; \u003cstrong\u003eRNA\u003c/strong\u003e: Ribonucleic acid; \u003cstrong\u003eRoB 2.0\u003c/strong\u003e: Risk of bias 2.0; \u003cstrong\u003eSARS-CoV-2\u003c/strong\u003e: Severe acute respiratory syndrome-related coronavirus 2; \u003cstrong\u003eWHO\u003c/strong\u003e: World Health Organization.\u003c/p\u003e"},{"header":"Declarations","content":"\u003ch2\u003eEthics approval and consent to participate\u003c/h2\u003e\n\u003cp\u003eResearch ethics board approval and consent were waived, because the conduct of this research will be based on published literature.\u003c/p\u003e\n\u003ch2\u003eConsent for publication\u003c/h2\u003e\n\u003cp\u003eNot applicable.\u003c/p\u003e\n\u003ch2\u003eAvailability of data and materials\u003c/h2\u003e\n\u003cp\u003eAll data generated or analyzed during this research will be included in the following full-text of the scoping review and/or its supplementary files.\u003c/p\u003e\n\u003ch2\u003eCompeting interests\u003c/h2\u003e\n\u003cp\u003eThe authors declare that they have no competing interests.\u003c/p\u003e\n\u003ch2\u003eFunding\u003c/h2\u003e\n\u003cp\u003eNone.\u003c/p\u003e\n\u003ch2\u003eAuthors\u0026rsquo; contributions\u003c/h2\u003e\n\u003cp\u003eCuncun Lu developed the research questions, the rest of other authors modified and improved them. Jieyun Li, Lufang Feng, Haitong Zhao and Kehu Yang established the search strategy. Jieyun Li, Lufang Feng and Cuncun Lu drafted the protocol. Jieyun Li, Lufang Feng, Haitong Zhao, Kehu Yang and Cuncun Lu reviewed and approved the final manuscript.\u003c/p\u003e\n\u003ch2\u003eAcknowledgements\u003c/h2\u003e\n\u003cp\u003eThe authors thank Howard White (Chief Executive Officer of Campbell Collaboration, Methodological expert) for his methodological guidance and proofreading of the manuscript.\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\n\u003cli\u003eKaur SP, and Gupta V. COVID-19 Vaccine: A comprehensive status report. Virus Res. 2020; 288:198114.\u003c/li\u003e\n\u003cli\u003eWHO, WHO Coronavirus Disease (COVID-19) Dashboard \u003ca href=\"https://covid19.who.int/\"\u003ehttps://covid19.who.int/\u003c/a\u003e.\u003cem\u003e [Accessed on November 14, 2020]\u003c/em\u003e\u003c/li\u003e\n\u003cli\u003eCunningham AL, Gar\u0026ccedil;on N, Leo O, Friedland LR, Strugnell R, Laup\u0026egrave;ze B, et al. Vaccine development: From concept to early clinical testing. Vaccine. 2016;34(52):6655-6664.\u003c/li\u003e\n\u003cli\u003eZhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270-273.\u003c/li\u003e\n\u003cli\u003eGraham BS. Rapid COVID-19 vaccine development. Science. 2020;368(6494):945-946.\u003c/li\u003e\n\u003cli\u003eWHO, DRAFT landscape of COVID-19 candidate vaccines \u003ca href=\"https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines\"\u003ehttps://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines\u003c/a\u003e/.\u003cem\u003e [Accessed on November 14, 2020]\u003c/em\u003e\u003c/li\u003e\n\u003cli\u003eDoshi P, Will covid-19 vaccines save lives? Current trials aren't designed to tell us. BMJ. 2020;371:m4037.\u003c/li\u003e\n\u003cli\u003eSeo SH and Y. Jang. Cold-adapted live attenuated sars-cov-2 vaccine completely protects human ace2 transgenic mice from sars-cov-2 infection. Vaccines. 2020;8(4):1-17.\u003c/li\u003e\n\u003cli\u003eZost SJ, Gilchuk P, Case JB, Binshtein E, Chen RE, Nkolola JP, et al. Potently neutralizing and protective human antibodies against SARS-CoV-2. Nature. 2020;584(7821):443-449.\u003c/li\u003e\n\u003cli\u003eWu S, Zhong G, Zhang J, Shuai L, Zhang Z, Wen Z, et al. A single dose of an adenovirus-vectored vaccine provides protection against SARS-CoV-2 challenge. Nat Commun. 2020;11(1):4081.\u003c/li\u003e\n\u003cli\u003eFolegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020;396(10249):467-478.\u003c/li\u003e\n\u003cli\u003eLi L, Guo P, Zhang X, Yu Z, Zhang W and Sun H. SARS-CoV-2 vaccine candidates in rapid development. Human Vaccines and Immunotherapeutics. 2020.\u003c/li\u003e\n\u003cli\u003eJackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, et al. An mRNA Vaccine against SARS-CoV-2-Preliminary Report. N Engl J Med. 2020;383(20):1920-1931.\u003c/li\u003e\n\u003cli\u003eTheobald N. Emerging vaccine delivery systems for COVID-19: Functionalised silica nanoparticles offer a potentially safe and effective alternative delivery system for DNA/RNA vaccines and may be useful in the hunt for a COVID-19 vaccine. Drug Discov Today. 2020;25(9):1556-1558.\u003c/li\u003e\n\u003cli\u003eLazarus JV, Ratzan SC, Palayew A, Gostin LO, Larson HJ, Rabin K, et al. A global survey of potential acceptance of a COVID-19 vaccine. Nat Med. 2020;1-4.\u003c/li\u003e\n\u003cli\u003eChen SY, Zhang C, Huang XF, Wang X, Zhao QJ. Enhanced vaccine accessibility through innovative regulatory sciences. Chin J New Drugs. 2017;26(20):2369-2375. \u003cem\u003e[In Chinese]\u003c/em\u003e\u003c/li\u003e\n\u003cli\u003eBastian H, Glasziou P and Chalmers I. Seventy-five trials and eleven systematic reviews a day: how will we ever keep up? PLoS Med. 2010;7(9):e1000326.\u003c/li\u003e\n\u003cli\u003eChalmers I, and Glasziou P. Avoidable waste in the production and reporting of research evidence. Lancet. 2009;374(9683):86-89.\u003c/li\u003e\n\u003cli\u003eBagdasarian N, Cross GB and Fisher D. Rapid publications risk the integrity of science in the era of COVID-19. BMC Med. 2020;8(1):192.\u003c/li\u003e\n\u003cli\u003ede Wit E, van Doremalen N, Falzarano D and Munster VJ. SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol. 2016;14(8):523-534.\u003c/li\u003e\n\u003cli\u003eMunn Z, Peters MDJ, Stern C, Tufanaru C, McArthur A and Aromataris E. Systematic review or scoping review? Guidance for authors when choosing between a systematic or scoping review approach. BMC Med Res Methodol. 2018;18(1):143.\u003c/li\u003e\n\u003cli\u003eTricco AC, Lillie E, Zarin W, O'Brien K, Colquhoun H, Kastner M, et al. A scoping review on the conduct and reporting of scoping reviews. BMC Med Res Methodol.2016;6:15.\u003c/li\u003e\n\u003cli\u003ePeters MDJ, Marnie C, Tricco AC, Pollock D, Munn Z, Alexander L, et al. Updated methodological guidance for the conduct of scoping reviews. JBI Evid Synth. 2020;18(10):2119-2126.\u003c/li\u003e\n\u003cli\u003eTricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. Ann Intern Med. 2018;169(7):467-473.\u003c/li\u003e\n\u003cli\u003eArksey H and O'Malley L. Scoping studies: towards a methodological framework. International Journal of Social Research Methodology. 2005;8(1):19-32.\u003c/li\u003e\n\u003cli\u003eMoher D, Liberati A, Tetzlaff J and Altman DG, Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7): e1000097.\u003c/li\u003e\n\u003cli\u003eSchulz KF, Altman DG and Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ. 2010;340:c332.\u003c/li\u003e\n\u003cli\u003eShea BJ, Reeves BC, Wells G, Thuku M, Hamel C, Moran J, et al., AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ. 2017;358: j4008.\u003c/li\u003e\n\u003cli\u003eLevac D, Colquhoun H and O'Brien KK, Scoping studies: advancing the methodology. Implementation Science. 2010;5(1):69.\u003c/li\u003e\n\u003cli\u003eOuzzani M, Hammady H, Fedorowicz Z and Elmagarmid A, Rayyan-a web and mobile app for systematic reviews. Syst Rev. 2016;5(1):210.\u003c/li\u003e\n\u003cli\u003eSterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.\u003c/li\u003e\n\u003cli\u003eVaismoradi M, Turunen H and Bondas T. Content analysis and thematic analysis: Implications for conducting a qualitative descriptive study. Nurs Health Sci. 2013;15(3):398-405.\u003c/li\u003e\n\u003c/ol\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":true,"highlight":"","institution":"","isAcceptedByJournal":false,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true},"keywords":"Vaccine, COVID-19, Research activity, Living review, Scoping review","lastPublishedDoi":"10.21203/rs.3.rs-112777/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-112777/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003e\u003cstrong\u003eBackground:\u003c/strong\u003e Coronavirus disease 2019 (COVID-19) has become a global public problem and a pandemic event. Since the epidemic outbreak, deaths and cumulative confirmed positive cases have continued rising rapidly worldwide. Vaccines are regarded as one of the most effective means of preventing and controlling an epidemic. With the spread of COVID-19, a large number amount of literature on vaccines has been published recently. There is a pressing need to map the research activities of COVID-19 vaccines.\u003c/p\u003e\u003cp\u003e\u003cstrong\u003eMethods:\u003c/strong\u003e Following Arksey and O’Malley’s framework and Joanna Briggs Institute (JBI) methodological guidance,\u003cstrong\u003e \u003c/strong\u003ea scoping review is proposed to summarize the extent/breadth, range, and nature of evidence in research related to COVID-19 vaccines. Based on the research questions we have developed by ours, a comprehensive search will be performed in Cochrane Library, Embase, PubMed, Web of Science, CNKI, CBM, VIP, and WanFang databases by two independent reviewers. According to our predefined inclusion criteria, pairs of reviewers will independently assess the eligibility of identified studies from the databases. Following literature selection, pairs of reviewers will extract relevant information related to our research questions. The methodological quality and reporting quality of key evidence types (i.e., randomized controlled trials, systematic reviews and meta-analyses) will be evaluated using commonly used tools, if possible. Qualitative synthesis and descriptive statistics will be used to summarize and present the results. In addition, new or updated meta-analysis will be conducted to pool the data available in included primary studies where possible. To track the trends in COVID-19 vaccines research, we plan to update our results every 2~3 months. Preparation of this scoping review protocol referred to PRISMA-P checklist, and the reporting of the following full-text will be using PRISMA-ScR guidelines.\u003c/p\u003e\u003cp\u003e\u003cstrong\u003eDiscussion:\u003c/strong\u003e We believe the results of this scoping review on COVID-19 vaccine will contribute to provide foundational knowledge, and have significant value for the research and practice of COVID-19 vaccines. The findings will also allow us to identify research gaps on this topic and help to guide the future research of COVID-19 vaccines well.\u003c/p\u003e","manuscriptTitle":"Vaccine Research in COVID-19: A Living Scoping Review Protocol","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2020-11-23 22:30:14","doi":"10.21203/rs.3.rs-112777/v1","editorialEvents":[{"type":"communityComments","content":1}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"1ee60418-7ed9-4e3a-8a6d-ab2753f09ab7","owner":[],"postedDate":"November 23rd, 2020","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"posted","subjectAreas":[{"id":1172496,"name":"Infectious Diseases"}],"tags":[],"updatedAt":"2021-04-28T13:44:32+00:00","versionOfRecord":[],"versionCreatedAt":"2020-11-23 22:30:14","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-112777","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-112777","identity":"rs-112777","version":["v1"]},"buildId":"cBFmMYwuxLRRLfASyISRj","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}